Market Flux Event

Helus Pharma Phase 3 HLP003 Trial Hits Primary Endpoint in Major Depression, Stock Surges 23%

Read this in the Market Flux app

Helus Pharma reported positive topline results from its Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder, sending shares of the Nasdaq-listed company up 23.2% in premarket trading on November 16. The drug met both the primary and all key secondary endpoints in the trial.

The primary endpoint showed a placebo-adjusted reduction of 7.6 points from baseline at Week 6 on the Montgomery-Asberg Depression Rating Scale, with a p-value below 0.0001. The APPROACH study enrolled 223 participants with moderate to severe MDD, defined as a MADRS score of 24 or higher, who were on a stable dose of antidepressant medication but responding inadequately. HLP003 holds Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

Helus Pharma entered the readout with approximately $171 million in cash. Phase 2 data had previously shown a mean roughly 23-point MADRS reduction from baseline at 12 months following two 16-milligram doses administered three weeks apart, with 100% response and 71% remission rates using a MADRS threshold of 10 or below.

© AI-generated summary is provided by Market Flux

Sources

  1. BioStocks$HELP topline data from Phase 3 APPROACH pivotal study of HLP003 in MDD in Q4 Cash $171M
  2. Briefingcom$LXEO: Lexeo Therapeutics reported interim Phase I/II data showing high-dose LX2020 reduced non-sustained ventricular tachycardia by 80% and premature ventricular contractions by 44%.
  3. GurufocusBioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
  4. Business WireEstrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
  5. TheTradeXchange$CGON - PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
  6. InvestingNuvation Bio presents long-term data on brain cancer drug
  7. OpenOutcrier$BLRX (+6.9% pre) BioLineRx initiates fourth cohort in GLIX1 brain tumor trial
  8. BPharmCatalyst$HELP announced positive Phase 3 APPROACH data for HLP003 (deuterated psilocin) as an adjunct in major depressive disorder (n=222). The trial met its primary endpoint with a 7.6-point placebo-adjusted MADRS reduction at Week 6 (p<0.0001), sustained at 7.0 points through Week 12. Week 6 response and remission rates were 56.3% and 50.9% versus 28.2% and 18.2% for placebo, with onset by Day 2. Three treatment-related SAEs occurred; Phase 3 EMBRACE results are expected in Q4 2027. $ACRS $LXEO $CRDF $OCS $HELP $DRTS $AKAN $INAB $XRTX $ADXN See More Pre-market Movers at BioPharmCatalyst in the Articles Menu